188 related articles for article (PubMed ID: 19821799)
1. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
van Besien K; Dew A; Lin S; Joseph L; Godley LA; Larson RA; Odenike T; Rich E; Stock W; Wickrema A; Artz AS
Leuk Lymphoma; 2009 Nov; 50(11):1809-17. PubMed ID: 19821799
[TBL] [Abstract][Full Text] [Related]
2. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.
Marsh RA; Kim MO; Liu C; Bellman D; Hart L; Grimley M; Kumar A; Jodele S; Myers KC; Chandra S; Leemhuis T; Mehta PA; Bleesing JJ; Davies SM; Jordan MB; Filipovich AH
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1625-31. PubMed ID: 24035782
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT.
Marsh RA; Lane A; Mehta PA; Neumeier L; Jodele S; Davies SM; Filipovich AH
Blood; 2016 Jan; 127(4):503-12. PubMed ID: 26644451
[TBL] [Abstract][Full Text] [Related]
4. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
[TBL] [Abstract][Full Text] [Related]
5. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
[TBL] [Abstract][Full Text] [Related]
6. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Marks DI; Lush R; Cavenagh J; Milligan DW; Schey S; Parker A; Clark FJ; Hunt L; Yin J; Fuller S; Vandenberghe E; Marsh J; Littlewood T; Smith GM; Culligan D; Hunter A; Chopra R; Davies A; Towlson K; Williams CD
Blood; 2002 Nov; 100(9):3108-14. PubMed ID: 12384406
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
Marsh RA; Bleesing JJ; Chandrakasan S; Jordan MB; Davies SM; Filipovich AH
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1641-5. PubMed ID: 24923536
[TBL] [Abstract][Full Text] [Related]
8. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; Mackinnon S
Blood; 2000 Oct; 96(7):2419-25. PubMed ID: 11001893
[TBL] [Abstract][Full Text] [Related]
9. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Cull GM; Haynes AP; Byrne JL; Carter GI; Miflin G; Rebello P; Hale G; Waldmann H; Russell NH
Br J Haematol; 2000 Mar; 108(4):754-60. PubMed ID: 10792280
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
[TBL] [Abstract][Full Text] [Related]
11. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Chakraverty R; Peggs K; Chopra R; Milligan DW; Kottaridis PD; Verfuerth S; Geary J; Thuraisundaram D; Branson K; Chakrabarti S; Mahendra P; Craddock C; Parker A; Hunter A; Hale G; Waldmann H; Williams CD; Yong K; Linch DC; Goldstone AH; Mackinnon S
Blood; 2002 Feb; 99(3):1071-8. PubMed ID: 11807015
[TBL] [Abstract][Full Text] [Related]
12. Age Impacts Risk of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Non-Severe Combined Immune Deficiency Inborn Errors of Immunity.
Fitch T; Lane A; McDonnell J; Bleesing J; Jordan M; Kumar A; Khandelwal P; Khoury R; Marsh R; Chandra S
Transplant Cell Ther; 2024 Jan; 30(1):101.e1-101.e12. PubMed ID: 37821080
[TBL] [Abstract][Full Text] [Related]
13. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.
Faulkner RD; Craddock C; Byrne JL; Mahendra P; Haynes AP; Prentice HG; Potter M; Pagliuca A; Ho A; Devereux S; McQuaker G; Mufti G; Yin JL; Russell NH
Blood; 2004 Jan; 103(2):428-34. PubMed ID: 12969983
[TBL] [Abstract][Full Text] [Related]
14. Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.
Solomon SR; Sizemore CA; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Bone Marrow Transplant; 2014 May; 49(5):616-21. PubMed ID: 24801098
[TBL] [Abstract][Full Text] [Related]
15. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Robinson SP; Goldstone AH; Mackinnon S; Carella A; Russell N; de Elvira CR; Taghipour G; Schmitz N;
Blood; 2002 Dec; 100(13):4310-6. PubMed ID: 12393626
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
Rzepecki P; Sarosiek T; Szczylik C
Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
Marsh JC; Gupta V; Lim Z; Ho AY; Ireland RM; Hayden J; Potter V; Koh MB; Islam MS; Russell N; Marks DI; Mufti GJ; Pagliuca A
Blood; 2011 Aug; 118(8):2351-7. PubMed ID: 21518925
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
Das-Gupta EP; Russell NH; Shaw BE; Pearce RM; Byrne JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):724-33. PubMed ID: 17531783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
